

Product Datasheet

GPER/GPR30 Antibody - BSA Free NBP1-31239

Unit Size: 100 ul

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Reviews: 1 Publications: 9

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP1-31239

Updated 2/21/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP1-31239



NBP1-31239


GPER/GPR30 Antibody - BSA Free

Product Information	
Unit Size	100 ul
Concentration	Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.01% Thimerosal
Isotype	IgG
Purity	Antigen Affinity-purified
Buffer	PBS, 20% Glycerol
Target Molecular Weight	42 kDa
Product Description	
Host	Rabbit
Gene ID	2852
Gene Symbol	GPER1
Species	Human, Porcine
Immunogen	Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human GPER/GPR30. The exact sequence is proprietary.
Product Application Details	
Applications	Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Knockdown Validated
Recommended Dilutions	Western Blot 1:500-1:3000, Flow Cytometry Reported in scientific literature (PMID 27899250), Immunohistochemistry, Immunocytochemistry/ Immunofluorescence Validated from a verified customer review, Immunohistochemistry-Paraffin Assay dependent, Knockdown Validated
Application Notes	WB As is commonly seen with membrane proteins, significant hydrophobicity can lead to aggregation following boiling of samples prior to SDS-PAGE and subsequent western blotting. We recommend to avoid boiling in this case. After harvesting lysate with RIPA buffer, sample loading buffer (including 2-ME) is directly added to the lysate. Samples are then mixed well and added directly without heating.




Images

Western Blot: GPER/GPR30 Antibody [NBP1-31239] - The MW of GPR30 is estimated to be 42 kDa, but higher MW sizes have been reported due to glycosylation and interaction with other proteins. Bands are identified as glycosylated and nonglycosylated based on reports cited in the text, but could include interaction with other proteins. For each GPER western, the membrane was stripped and reprobed for b-actin as a loading control. Quantitation of GPER was evaluated by summing all immunoreactive bands and dividing by b-actin, then normalizing to HBEC2-KT in each blot. Image collected and cropped by CiteAb from the following publication ([biomedcentral.com/1471-2407/12/624](https://doi.org/10.1186/1471-2407-12-624)), licensed under a CC-BY license.




Immunocytochemistry/Immunofluorescence: GPER/GPR30 Antibody [NBP1-31239] - Detection of GPER/GPR30 in HUVEC nucleus. Image courtesy of a product review by Dr. Subhadeep Chakrabarti of University of Alberta.


Western Blot: GPER/GPR30 Antibody [NBP1-31239] - A. 50 ug 293T whole cell lysate/extract. B. 50 ug whole cell lysate/extract of GFP-human GPR30-transfected 293T cells (No boiling). C. 50 ug whole cell lysate/extract of GFP-human GPR30 and GPR30 siRNA-transfected 293T cells (No boiling). 5 % SDS-PAGE GPR30 antibody) dilution: 1:1000




Western Blot: GPER/GPR30 Antibody [NBP1-31239] - AhR & GPR30 receptors are present & functional in the MCF10AT1 cells. (A) RT-qPCR analysis of AhR & GPR30 mRNA expression levels represented in arbitrary units (a.u.) in the MCF10AT1 & MCF10CA1a.cl1 cells. MCF-7 cells were used as a control. Values represent mean \pm SD of three independent experiments conducted in triplicate. (B) Representative Western blot analyses from three independent experiments of AhR & GPR30 protein expression in MCF10AT1 & MCF10CA1a.cl1 cells. MCF-7 cells were used as a control. (C) XRE-luciferase activity following 8 h exposure of MCF10AT1 cells to ITE at the indicated concentrations. TCDD 10⁻⁷ M was used as a control & results were expressed as % of TCDD 10⁻⁷ M activity. ****p* < 0.001 in Student t-test. (D) XRE-luciferase activity upon 8 h of exposure to ITE 10⁻¹⁰ M alone or in combination with GNF351 at the indicated concentrations. TCDD 10⁻⁷ M was used as a control, & results were expressed as % of TCDD 10⁻⁷ M activity. Student t-tests revealed the statistically significant differences between unexposed & exposed cells: ****p* < 0.001; & between ITE & ITE +GNF351: ####*p* < 0.001. Values in (C,D) represent mean \pm SD of three independent experiments. (E) Representative Western blot analyses from three independent experiments of the phospho-MAPK/MAPK ratio upon exposure of MCF10AT1 cells to G1 (GPR30 agonist) for the times indicated, in the presence or absence of a 2 h pre-treatment with G15 (GPR30 antagonist). Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/32670863>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10⁻¹⁰ M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10⁻¹⁰ M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean \pm SD of 2 independent experiments, in triplicate). ****p* < 0.001, **p* < 0.05 vs. their respective unexposed; ####*p* < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/32670863>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Human endothelial cells express GPR30 protein in the cell nucleus. (A) Confluent monolayers of HUVECs from 3 different cords were lysed & the protein lysates were immunoblotted for GPR30. α -tubulin was used as loading control. (B) HUVEC monolayers at 30–40% confluence were treated with 40 nM siRNA (control or GPR30_4) for 48 hours prior to lysis followed by immunoblotting of the cell lysates for GPR30. α -tubulin was used as loading control. Data shown are mean \pm SEM of 4 independent experiments. ** & ## indicate $p < 0.01$ compared to untreated & control siRNA-treated cells, respectively. (C) Confluent HUVECs grown on glass coverslips were fixed, permeabilized & immunostained with anti-GPR30 antibody. Nuclei were stained with Hoechst33342 dye. The merged image shows GPR30 (red) & nuclei (blue) in pseudocolor. Representative images from 3 independent experiments are shown. Bar, 20 μ m. (D) Confluent HUVECs were lysed & fractionated into cytosolic (C) & nuclear (N) fractions prior to western blotting for eNOS, GPR30, p65, α -tubulin & c-Jun. A representative set of images (obtained from different membranes) from 3 independent experiments is shown. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/23285008>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10–10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10–10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean \pm SD of 2 independent experiments, in triplicate). *** $p < 0.001$, * $p < 0.05$ vs. their respective unexposed; ### $p < 0.001$ siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/32670863>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10–10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10–10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean \pm SD of 2 independent experiments, in triplicate). *** $p < 0.001$, * $p < 0.05$ vs. their respective unexposed; ### $p < 0.001$ siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/32670863>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Duliban M, Pawlicki P, Kamińska A et al. Status of estrogen receptor expression and epigenetic methylation in Leydig cells after exposure to metalloestrogen - selenium *Reproductive Toxicology* 2023-05-01 [PMID: 37142062]

Torres-Lopez L, Olivas-Aguirre M, Villatoro-Gomez K, Dobrovinskaya O The G-Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Proliferation and Causes Apoptosis in Leukemia Cell Lines of T Lineage *Frontiers in Cell and Developmental Biology* 2022-02-14 [PMID: 35237599] (ICC/IF, Human)

Donini, C F, El Helou, M Et al. Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay. *Front Oncol* 2020-07-17 [PMID: 32670863] (FLOW, Human)

Details:

Citation using the Alexa Fluor 647 format of this antibody.

Torres-Lopez L, Maycotte P, Linan-Rico A et al. Tamoxifen induces toxicity, causes autophagy, and partially reverses dexamethasone resistance in Jurkat T cells *J Leukoc Biol* 2019-01-16 [PMID: 30645008] (WB, Human)

Zane M, Parello C, Pennelli G et al. Estrogen and thyroid cancer is a stem affair: A preliminary study *Biomed. Pharmacother* 2017-01-01 [PMID: 27899250] (FLOW, Human)

Teng Y, Radde BN, Litchfield LM et al. Dehydroepiandrosterone Activation of G-protein-Coupled Estrogen Receptor Rapidly Stimulates microRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. *J. Biol. Chem.* 2015-05-11 [PMID: 25969534] (WB, Human)

Jala VR, Radde BN, Haribabu B, Klinge CM. Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer. *BMC Cancer* 2012-12-28 [PMID: 23273253] (WB, Human)

Chakrabarti S, Davidge ST. G-Protein Coupled Receptor 30 (GPR30): A Novel Regulator of Endothelial Inflammation *PLoS One* 2012-01-01 [PMID: 23285008] (WB, Human)

Tian R, Wang Z, Shi Z et al. Differential expression of G-protein-coupled estrogen receptor-30 in human myometrial and uterine leiomyoma smooth muscle *Fertil Steril* 2012-10-06 [PMID: 23043685] (WB, IF/IHC, ICC/IF, Human)





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP1-31239

HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control
NBP1-88096PEP	GPER/GPR30 Recombinant Protein Antigen

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-31239

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

